InvestorsHub Logo
Post# of 252199
Next 10
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

Re: oc631 post# 153229

Thursday, 11/29/2012 9:02:06 AM

Thursday, November 29, 2012 9:02:06 AM

Post# of 252199
Evolution in the HCV treatment paradigm

If indeed there is different potency in different genotypes as seen in POSITRON trial, ideally we'll have different regimens for them (also for subgroups like naïve, experienced etc), but my guess is there would still be one regimen to start with and a more potent one will follow. One observation that backs this approach is this line from GILD's PR posted by Roy in #msg-81844469:

All patients receiving sofosbuvir/RBV became HCV RNA negative on treatment and relapse accounted for all virologic failures.

So, there was no resistance rather it was lack of full clearance of the virus, and these patients can go on and receive a more potent sofosbuvir containing regimen like you've suggested in #msg-81881061. Perhaps there will be a predictor such as patients on sofosbuvir/RBV not achieving undetectable after 4 weeks, should be given GS-5885 in addition and be dosed for 12 more weeks with full regimen. Perhaps all GT3 patients should get a more potent regimen, but I still think naïve will do better. Will have better understanding with FISSION and FUSION data.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.